Evidence map›Paper›PMID 40035549›Full record

ArticleAntimicrobial agents and chemotherapy2025

Incidence of fidaxomicin allergy in patients with macrolide allergies: a large database analysis.

Chia-Yu Chiu, Daniel B Chastain, Madison E Salam, Joseph Sassine, Andrés F Henao-Martínez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chia-Yu ChiuDepartment of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, Colorado, USA.ORCID 0000-0002-5241-3435
Daniel B ChastainDepartment of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia, USA.
Madison E SalamDepartment of Pharmacy, University of Colorado Hospital, Aurora, Colorado, USA.
Joseph SassineDepartment of Medicine, Infectious Diseases Section, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0001-8730-8929
Andrés F Henao-MartínezDepartment of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, Colorado, USA.ORCID 0000-0001-7363-8652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fidaxomicin may exhibit cross-reactivity in patients with known macrolide allergies. In this analysis, compared to patients without macrolide allergies, the odds of fidaxomicin allergy were 2.31, 8.37, and 1.58 times higher in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively; the absolute risk of fidaxomicin allergy was 0.033, 0.01, and 0.039 in patients with azithromycin, clarithromycin, and erythromycin allergies, respectively. The highest risk of anaphylaxis and angioedema was observed within 1 year of a non-fidaxomicin macrolide allergy.

Indexed as

Anti-Bacterial AgentsDrug HypersensitivityFidaxomicinMacrolidesAdultAnaphylaxisAzithromycinClarithromycinCross ReactionsDatabases, FactualErythromycinFemaleHumansIncidenceMaleMiddle AgedAnti-Bacterial AgentsAzithromycinClarithromycinErythromycinFidaxomicinMacrolidesazithromycinclarithromycindrug hypersensitivityerythromycinfidaxomicin

Identifiers

PMID40035549
PMCPMC11963595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.